📅 PUBMED DAILY TRIAGE — 2026-07-11 Window: 2026-07-10T00:00:00Z → 2026-07-11T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~120 | Candidates evaluated: ~120 High priority: 8 | Standard: 13 | Low/archive: 3 | Unsolicited finds: 1 Run status: PARTIAL_SUCCESS (Attempt 3 repair from salvage; PMID arrays partially reconstructed)
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
T1_hematologic_malignancies
42430236 · Constitutive DUSP2 expression enhances lymphoid cell proliferation by activating CDK1 and promotes lymphomagenesis · 9/10 · DUSP2 activates CDK1 via a non-catalytic structural motif recruiting CDC25 phosphatases, identifying a novel therapeutic target in B- and T-cell malignancies.
T3_early_cancer_detection
42430497 · A scalable deep-learning framework for cancer detection using cell-free DNA shallow whole-genome sequencing · 10/10 · UNITE tumor-naive AI detects 26 cancer types from 0.1x cfDNA WGS with 21-31% stage I-II sensitivity at 95% specificity in a 2063-sample validation cohort.
T4_ai_clinical_diagnostics
42430497 · A scalable deep-learning framework for cancer detection using cell-free DNA shallow whole-genome sequencing · 10/10 · (also matched T3; see above)
T5_precision_oncology
42430697 · Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes · 8/10 · ERBB2 amplification is more prevalent in African ancestry EC patients (12% vs 7%), highlighting equity gaps in HER2-targeted precision therapy access.
T6_novel_therapeutics
42430444 · The efficacy of immunotherapy in glioma requires distal B cell responses in tumor-draining lymph nodes · 8/10 · CTLA-4 blockade in glioma requires germinal center B cell activation in cervical lymph nodes; glioma-reactive IgG promotes phagocytosis in the TME. 42430699 · Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers · 8/10 · MSI-H BTC: 73% 2-year OS, 23.1% surgical conversion, 50% pathological CR; supports upfront dMMR/MSI-H testing. 42429576 · Neoadjuvant immunotherapy for resectable cutaneous melanoma: a nationwide population-based cohort · 8/10 · Swedish nationwide cohort (n=279): 43% MPR, 37% CR, 69% 24-month EFS — real-world results match RCT benchmarks.
T7_cardiovascular_metabolic
42429894 · Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies · 8/10 · Largest observational meta-analysis (n=75,833 HF patients): GLP-1 RA + SGLT2i reduces all-cause mortality (RR 0.62), hospitalization (RR 0.89), and worsening HF (RR 0.74) vs. SGLT2i alone.
T9_rare_diseases
42430850 · FRRS1L gene replacement ameliorates disease phenotypes in the mouse model of developmental and epileptic encephalopathy 37 · 9/10 · First preclinical gene therapy POC for DEE37: intrathecal AAV9 FRRS1L restores synaptic AMPAR and rescues structural, ECoG, and behavioral phenotypes dose-dependently. 42430699 · Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers · 8/10 · (also matched T6; see above)
T2_cbc_diagnostics_ml: No high-priority finds today (0 results in CRDT window) T8_aging_longevity: No high-priority finds today (best candidate scored 7/10) sentinel: No high-priority finds today (best candidate scored 4/10)
🟢⚪ STANDARD (5-7) — Top by Topic
T1_hematologic_malignancies
42429854 · Epigenomic dysregulation in the bone marrow mesenchymal stem cells of acquired aplastic anemia patients · 7/10 · Genomics/Precision Medicine 42430569 · Intensified R-MPVA with sequential etoposide/ifosfamide for PCNSL (60-70 yrs): 81.3% CR, 3-yr EFS 40.2%, OS 63.2% · 5/10 · Treatment Innovation
T6_novel_therapeutics
42430019 · Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in TNBC following neoadjuvant chemo-immunotherapy · 6/10 · Public Health 42429963 · Single-cell hdWGCNA identifies CIP-linked CD4+ T-cell subsets driving immunotherapy response and prognosis in lung cancer · 6/10 · Genomics/Precision Medicine 42430190 · Single-cell sequencing profiling of intratumoral heterogeneity and immunosuppressive microenvironment in thyroid cancer and LN metastases · 6/10 · Genomics/Precision Medicine
T7_cardiovascular_metabolic
42430855 · Endothelial Cells at the Crossroad of Atherosclerosis and MASLD: A Unifying Target for Dual Treatment · 6/10 · Treatment Innovation
T8_aging_longevity
42427166 · APOE-epsilon4 carriership and dementia risk over 10 years among Asian American and White older adults · 7/10 · Public Health 42429048 · Single-cell atlas reveals a WT1-mediated axis driving granulosa cell senescence in human ovarian aging · 6/10 · Genomics/Precision Medicine
T9_rare_diseases
42430813 · Beyond citrulline: The diagnostic accuracy of amino acid ratios in neonatal intrahepatic cholestasis caused by citrin deficiency · 7/10 · Diagnostics 42429952 · Insight into Natural History and Phenotype in Untreated Adults with X-Linked Hypophosphatemia · 7/10 · Public Health 42429855 · Structural Connectome Alterations in Alternating Hemiplegia of Childhood · 7/10 · Diagnostics 42429854 · Epigenomic dysregulation in BM-MSCs of acquired aplastic anemia patients · 7/10 · Genomics/Precision Medicine 42428635 · Geographical Disparities in the Detection and Certification of Systemic Amyloidosis in Japan: 2015-2024 · 6/10 · Public Health
sentinel
42430886 · Local ablative treatment and continuation of systemic therapy for oligoprogressive metastatic breast cancer · 4/10 · Treatment Innovation
🗃 LOW / ARCHIVE (≤3)
42430341 · Clinical characteristics and outcomes of Hodgkin Lymphoma: A single institution retrospective cohort study · 3/10 · Routine single-institution HL outcomes; known predictors confirmed in Jordanian cohort; T1 completeness only. 42430696 · First-In-Human [177Lu]Lu-FAPI-XT Therapy Combined With Anti-PD-1 Antibody in Metastatic Colon Cancer · 3/10 · Title only; novel FAPI radiotheranostic concept; score capped at 3 per title-only rule. Monitor for follow-up cohort reports. 42430142 · GLP-1 Drugs Associated With Smell and Taste Disruptions · 3/10 · Title only; emerging safety signal for GLP-1 RAs in JAMA; score capped at 3 per title-only rule.
💡 UNSOLICITED FINDS
42430886 · Local ablative treatment and continuation of systemic therapy for oligoprogressive metastatic breast cancer · 4/10 · Local ablative treatment plus systemic therapy continuation for oligoprogressive MBC is feasible per Dutch retrospective cohort; supports this as a practiced strategy pending RCT evidence.
📊 TODAY'S BREAKDOWN
By research category: Treatment Innovation: 10 Genomics/Precision Medicine: 5 Public Health: 5 Diagnostics: 2 Early Detection: 1 Drug Development: 1
By evidence maturity: Exploratory: 14 Validated: 9 Potentially Practice-Changing: 1
By source type: peer_reviewed 24 | preprint 0
By watchlist topic: T1_hematologic_malignancies: reviewed=15, retained=4, best=9/10 T2_cbc_diagnostics_ml: reviewed=0, retained=0, no finds T3_early_cancer_detection: reviewed=15, retained=1, best=10/10 T4_ai_clinical_diagnostics: reviewed=15, retained=1, best=10/10 T5_precision_oncology: reviewed=7, retained=1, best=8/10 T6_novel_therapeutics: reviewed=15, retained=7, best=8/10 T7_cardiovascular_metabolic: reviewed=15, retained=3, best=8/10 T8_aging_longevity: reviewed=13, retained=2, best=7/10 T9_rare_diseases: reviewed=15, retained=7, best=9/10 sentinel: reviewed=10, retained=1, best=4/10
Topics with zero 8+ articles this run: T2_cbc_diagnostics_ml, T8_aging_longevity, sentinel
🔧 RUN NOTES
- Attempt 3 repair from salvage bundle (attempt 2). All article data preserved; only concrete validator errors corrected.
- PMID 42430696 (FAPI radiotheranostic FIH): triage_score corrected from 6 to 3 (title-only cap ≤3); pipeline_priority corrected to LOW.
- PMID 42430142 (JAMA GLP-1 smell/taste): triage_score corrected from 5 to 3 (title-only cap ≤3); pipeline_priority corrected to LOW.
- Both title-only records retain their biomedical notes and triage_reason; only the score and priority fields changed to satisfy the schema rule.
- PMID coverage arrays partially reconstructed from retained articles only (discarded LOW-scoring candidates' PMIDs not preserved in salvage bundle).
- T2 (CBC/ML diagnostics): 0 results in CRDT window; no candidates reviewed.
- T8 (Aging/longevity): 13 candidates reviewed (human MeSH filter applied to exclude animal biology noise).
- T5 (Precision oncology): 7 candidates in window (smaller daily CRDT volume).